MX378790B - Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. - Google Patents
Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.Info
- Publication number
- MX378790B MX378790B MX2017000821A MX2017000821A MX378790B MX 378790 B MX378790 B MX 378790B MX 2017000821 A MX2017000821 A MX 2017000821A MX 2017000821 A MX2017000821 A MX 2017000821A MX 378790 B MX378790 B MX 378790B
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- cells
- treatment
- autoimmune diseases
- protein
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461999241P | 2014-07-21 | 2014-07-21 | |
| PCT/US2015/041177 WO2016014428A2 (en) | 2014-07-21 | 2015-07-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017000821A MX2017000821A (es) | 2017-08-18 |
| MX378790B true MX378790B (es) | 2025-03-10 |
Family
ID=55163946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000821A MX378790B (es) | 2014-07-21 | 2015-07-20 | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
| MX2021000083A MX2021000083A (es) | 2014-07-21 | 2017-01-18 | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000083A MX2021000083A (es) | 2014-07-21 | 2017-01-18 | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20170051029A1 (OSRAM) |
| EP (2) | EP3172227B9 (OSRAM) |
| JP (2) | JP6768633B2 (OSRAM) |
| KR (1) | KR102493543B1 (OSRAM) |
| CN (2) | CN106795213B (OSRAM) |
| AU (3) | AU2015292889C1 (OSRAM) |
| CA (1) | CA2954847A1 (OSRAM) |
| DK (1) | DK3172227T3 (OSRAM) |
| EA (2) | EA038361B1 (OSRAM) |
| ES (1) | ES2763198T3 (OSRAM) |
| GB (1) | GB2538666A (OSRAM) |
| HU (1) | HUE046065T2 (OSRAM) |
| IL (3) | IL289475B2 (OSRAM) |
| LT (1) | LT3172227T (OSRAM) |
| MX (2) | MX378790B (OSRAM) |
| PL (1) | PL3172227T3 (OSRAM) |
| PT (1) | PT3172227T (OSRAM) |
| RS (1) | RS59789B1 (OSRAM) |
| SG (2) | SG10202010158TA (OSRAM) |
| SI (1) | SI3172227T1 (OSRAM) |
| WO (1) | WO2016014428A2 (OSRAM) |
| ZA (1) | ZA201700344B (OSRAM) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105121715B (zh) | 2012-12-11 | 2018-10-26 | 艾伯特叶史瓦大学爱因斯坦医学院 | 高通量受体:配体鉴定方法 |
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CA3022331A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| CN109475628A (zh) | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| CN110167957A (zh) * | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| WO2018112069A1 (en) | 2016-12-13 | 2018-06-21 | Delinia, Inc. | Multivalent regulatory t cell modulators |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| EP3604538A4 (en) | 2017-03-29 | 2020-12-30 | University of Miyazaki | LONG-ACTING ADRENOMEDULLINE DERIVATIVE |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| WO2019104092A1 (en) | 2017-11-21 | 2019-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3083941A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Il-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
| AU2018394189B2 (en) | 2017-12-27 | 2023-12-21 | Kyowa Kirin Co., Ltd. | IL-2 variant |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| JP7534215B2 (ja) | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
| WO2019144309A1 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine Fusion Proteins |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| US11359000B2 (en) | 2018-03-28 | 2022-06-14 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
| EP3552738B1 (en) * | 2018-04-12 | 2024-07-31 | Sandvik Machining Solutions AB | A method of producing an additive manufactured object |
| WO2019246404A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CA3108865A1 (en) | 2018-08-06 | 2020-02-13 | Medikine, Inc. | Il-2 receptor binding compounds |
| US12403181B2 (en) | 2018-08-13 | 2025-09-02 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| JP7543269B2 (ja) | 2018-12-21 | 2024-09-02 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ヒトインターロイキン２の変異体またはその誘導体 |
| WO2020160242A1 (en) | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| CA3129317A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| KR20210128443A (ko) | 2019-02-15 | 2021-10-26 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6 항체 및 이의 용도 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CA3148505A1 (en) * | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Novel il-2 fusion molecules |
| JP7427286B2 (ja) | 2019-11-05 | 2024-02-05 | メディカイン、インコーポレイテッド | ＩＬ－２ＲβγＣ結合化合物 |
| AU2020378282B2 (en) | 2019-11-05 | 2023-05-18 | Medikine, Inc. | Dual IL-2R and IL-7R binding compounds |
| KR20220139293A (ko) | 2019-12-12 | 2022-10-14 | 일투 파마 | 인터류킨 2 키메라 구축물 |
| US20210188934A1 (en) * | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| US11491205B2 (en) | 2020-01-14 | 2022-11-08 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| KR20220139918A (ko) | 2020-02-03 | 2022-10-17 | 메디카인 인코포레이티드 | IL-7Rαγc 결합 화합물 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| US20230340054A1 (en) * | 2020-09-01 | 2023-10-26 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| IL302276A (en) | 2020-10-23 | 2023-06-01 | Asher Biotherapeutics Inc | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| TW202227123A (zh) | 2020-11-13 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種包含人白細胞介素２變體或其衍生物的醫藥組成物及其用途 |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| MX2023011930A (es) | 2021-04-09 | 2024-03-11 | Selecta Biosciences Inc | Nanoportadores sintéticos que comprenden un inmunosupresor en combinación con antagonistas del receptor de il-2 de alta afinidad para mejorar la tolerancia inmune. |
| MX2024004291A (es) | 2021-10-06 | 2024-06-28 | Iltoo Pharma | Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados. |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| CN115322260A (zh) * | 2022-06-13 | 2022-11-11 | 杭州高田生物医药有限公司 | 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用 |
| CA3265946A1 (en) | 2022-09-12 | 2024-03-21 | Univ Sorbonne | INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS |
| IL319951A (en) | 2022-11-30 | 2025-05-01 | Integral Molecular Inc | Antibodies targeting claudin 6, including its bispecific formats |
| AU2024207151A1 (en) | 2023-01-09 | 2025-06-19 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| DE60222914T2 (de) | 2001-07-27 | 2008-07-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| JP2007500132A (ja) * | 2003-07-25 | 2007-01-11 | アムジェン インコーポレイテッド | Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法 |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| AU2005227263A1 (en) * | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| US7750124B2 (en) * | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| MX2011007647A (es) * | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| CN102356092B (zh) * | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| IL300733B1 (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| CN102174111B (zh) * | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
| LT3075745T (lt) * | 2011-02-10 | 2018-11-26 | Roche Glycart Ag | Mutavę interleukino-2 polipeptidai |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| JP2014094898A (ja) * | 2012-11-07 | 2014-05-22 | Univ Of Tsukuba | 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| CA3093606A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
| CN103193887B (zh) * | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
-
2015
- 2015-07-20 DK DK15824955T patent/DK3172227T3/da active
- 2015-07-20 EP EP15824955.7A patent/EP3172227B9/en active Active
- 2015-07-20 KR KR1020177001922A patent/KR102493543B1/ko active Active
- 2015-07-20 JP JP2017504096A patent/JP6768633B2/ja not_active Expired - Fee Related
- 2015-07-20 SG SG10202010158TA patent/SG10202010158TA/en unknown
- 2015-07-20 PL PL15824955T patent/PL3172227T3/pl unknown
- 2015-07-20 AU AU2015292889A patent/AU2015292889C1/en not_active Withdrawn - After Issue
- 2015-07-20 LT LTEP15824955.7T patent/LT3172227T/lt unknown
- 2015-07-20 GB GB1615553.3A patent/GB2538666A/en not_active Withdrawn
- 2015-07-20 MX MX2017000821A patent/MX378790B/es unknown
- 2015-07-20 SG SG11201700514SA patent/SG11201700514SA/en unknown
- 2015-07-20 SI SI201530968T patent/SI3172227T1/sl unknown
- 2015-07-20 EA EA201790213A patent/EA038361B1/ru unknown
- 2015-07-20 PT PT158249557T patent/PT3172227T/pt unknown
- 2015-07-20 CN CN201580050979.6A patent/CN106795213B/zh not_active Expired - Fee Related
- 2015-07-20 CN CN202111371055.XA patent/CN114133456A/zh active Pending
- 2015-07-20 IL IL289475A patent/IL289475B2/en unknown
- 2015-07-20 EA EA202190903A patent/EA202190903A3/ru unknown
- 2015-07-20 RS RS20191448A patent/RS59789B1/sr unknown
- 2015-07-20 CA CA2954847A patent/CA2954847A1/en active Pending
- 2015-07-20 WO PCT/US2015/041177 patent/WO2016014428A2/en not_active Ceased
- 2015-07-20 EP EP19188596.1A patent/EP3587444A1/en not_active Withdrawn
- 2015-07-20 ES ES15824955T patent/ES2763198T3/es active Active
- 2015-07-20 HU HUE15824955A patent/HUE046065T2/hu unknown
-
2016
- 2016-09-14 US US15/265,770 patent/US20170051029A1/en not_active Abandoned
- 2016-09-14 US US15/265,764 patent/US20170037102A1/en not_active Abandoned
-
2017
- 2017-01-10 IL IL250024A patent/IL250024B/en active IP Right Grant
- 2017-01-16 ZA ZA2017/00344A patent/ZA201700344B/en unknown
- 2017-01-18 MX MX2021000083A patent/MX2021000083A/es unknown
- 2017-07-28 US US15/662,633 patent/US20170327555A1/en not_active Abandoned
-
2019
- 2019-01-17 US US16/250,255 patent/US20190375812A1/en not_active Abandoned
-
2020
- 2020-04-07 US US16/841,815 patent/US20210047382A1/en not_active Abandoned
- 2020-05-27 AU AU2020203480A patent/AU2020203480A1/en not_active Abandoned
- 2020-09-02 JP JP2020147441A patent/JP2021006038A/ja active Pending
- 2020-10-26 IL IL278299A patent/IL278299B/en unknown
-
2021
- 2021-12-20 US US17/556,208 patent/US20220112260A1/en not_active Abandoned
-
2022
- 2022-07-11 AU AU2022204946A patent/AU2022204946A1/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378790B (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
| ECSP18062614A (es) | Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes | |
| ECSP20081591A (es) | Proteínas de fusión que comprenden progranulina | |
| MX2017014822A (es) | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. | |
| MX2017000833A (es) | Variantes il-2 modificadas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunitarias. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| UY36021A (es) | Proteìnas fc multimèricas | |
| GEP20237528B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| CY1119840T1 (el) | Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων | |
| AR099289A1 (es) | Proteínas de fusión de interleucina-2 y usos de las mismas | |
| CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| DK3180018T3 (da) | Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein | |
| MX384490B (es) | Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias. | |
| MX2018008339A (es) | Multimeros fc de inmunoglobulina g recombinante. | |
| MX2017005325A (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| SV2018005714A (es) | Composiciones y metodos para disminuir la expresion de tau | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| UY36171A (es) | Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa | |
| CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| MX373805B (es) | Agonistas de receptor fgf21 y usos del mismo. | |
| TWD196337S (zh) | 口腔保健器具（一） | |
| ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
| AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
| EA201990824A1 (ru) | Антитела, которые связываются с интерлейкином-2, и их применение |